Daymark Wealth Partners LLC Has $1.19 Million Stake in CVS Health Co. (NYSE:CVS)

Daymark Wealth Partners LLC reduced its holdings in CVS Health Co. (NYSE:CVS) by 70.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,537 shares of the pharmacy operator’s stock after selling 64,160 shares during the quarter. Daymark Wealth Partners LLC’s holdings in CVS Health were worth $1,191,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Perfromance Wealth Partners LLC bought a new stake in shares of CVS Health during the fourth quarter worth $475,000. Fort Washington Investment Advisors Inc. OH grew its holdings in CVS Health by 17.6% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,089,654 shares of the pharmacy operator’s stock worth $48,915,000 after acquiring an additional 163,148 shares during the last quarter. Ballentine Partners LLC increased its position in CVS Health by 17.5% in the 4th quarter. Ballentine Partners LLC now owns 5,314 shares of the pharmacy operator’s stock valued at $239,000 after acquiring an additional 793 shares in the last quarter. LaFleur & Godfrey LLC lifted its position in shares of CVS Health by 49.9% during the fourth quarter. LaFleur & Godfrey LLC now owns 4,836 shares of the pharmacy operator’s stock worth $217,000 after purchasing an additional 1,610 shares in the last quarter. Finally, AHL Investment Management Inc. grew its stake in shares of CVS Health by 1.7% during the fourth quarter. AHL Investment Management Inc. now owns 43,316 shares of the pharmacy operator’s stock valued at $1,944,000 after purchasing an additional 713 shares during the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Stock Down 0.2 %

NYSE:CVS opened at $53.05 on Thursday. The firm has a market capitalization of $66.76 billion, a price-to-earnings ratio of 13.46, a price-to-earnings-growth ratio of 0.80 and a beta of 0.59. The company has a quick ratio of 0.59, a current ratio of 0.80 and a debt-to-equity ratio of 0.80. CVS Health Co. has a twelve month low of $43.56 and a twelve month high of $80.75. The stock’s 50 day moving average price is $51.26 and its two-hundred day moving average price is $56.26.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.01. The firm had revenue of $95.43 billion during the quarter, compared to analysts’ expectations of $92.72 billion. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. The company’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter last year, the company posted $2.21 earnings per share. Equities research analysts expect that CVS Health Co. will post 5.22 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Thursday, January 23rd will be paid a dividend of $0.665 per share. The ex-dividend date is Thursday, January 23rd. This represents a $2.66 annualized dividend and a dividend yield of 5.01%. CVS Health’s dividend payout ratio is currently 67.51%.

Analysts Set New Price Targets

Several research analysts have issued reports on CVS shares. TD Cowen upped their price objective on CVS Health from $73.00 to $80.00 and gave the stock a “buy” rating in a report on Monday, November 25th. Royal Bank of Canada decreased their price target on CVS Health from $68.00 to $58.00 and set an “outperform” rating on the stock in a report on Friday, November 15th. StockNews.com downgraded shares of CVS Health from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Evercore ISI increased their price target on shares of CVS Health from $62.00 to $75.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th. Finally, Truist Financial decreased their price objective on CVS Health from $67.00 to $60.00 and set a “buy” rating for the company in a research report on Monday, January 6th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $68.71.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.